22.29
Staar Surgical Co stock is traded at $22.29, with a volume of 278.56K.
It is up +2.05% in the last 24 hours and down -0.70% over the past month.
Staar Surgical Co is a manufacturer of lenses. It designs, develops, manufactures, and sells implantable lenses for the eye and delivery systems used to deliver the lenses into the eye. The company offers two types of products: Implantable Collamer lenses (ICL), which are used in refractive surgery. The company generates almost all of its revenue from the sale of its ICL products. Geographically, the company generates key revenue from Foreign sales.
See More
Previous Close:
$21.84
Open:
$22.03
24h Volume:
278.56K
Relative Volume:
0.45
Market Cap:
$1.12B
Revenue:
$290.38M
Net Income/Loss:
$-21.03M
P/E Ratio:
-51.90
EPS:
-0.4294
Net Cash Flow:
$-54.99M
1W Performance:
-0.41%
1M Performance:
-0.70%
6M Performance:
-9.88%
1Y Performance:
-13.61%
Staar Surgical Co Stock (STAA) Company Profile
Name
Staar Surgical Co
Sector
Industry
Phone
(626) 303-7902
Address
1911 WALKER AVE, MONROVIA, CA
Compare STAA vs ISRG, BDX, RMD, ALC, MDLN
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
|
STAA
Staar Surgical Co
|
22.29 | 1.12B | 290.38M | -21.03M | -54.99M | -0.4294 |
|
ISRG
Intuitive Surgical Inc
|
426.15 | 150.55B | 11.03B | 3.16B | 3.22B | 8.7251 |
|
BDX
Becton Dickinson Co
|
192.66 | 52.48B | 21.37B | 1.41B | 3.07B | 3.9437 |
|
RMD
Resmed Inc
|
241.45 | 33.96B | 5.54B | 1.52B | 1.74B | 10.37 |
|
ALC
Alcon Inc
|
66.65 | 32.22B | 10.63B | 819.00M | 1.59B | 1.6577 |
|
MDLN
Medline Inc
|
36.59 | 32.11B | 29.14B | 1.07B | 1.05B | 1.1956 |
Staar Surgical Co Stock (STAA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Sep-29-26 | Upgrade | Stifel | Hold → Buy |
| Jul-28-26 | Initiated | UBS | Sell |
| May-14-26 | Upgrade | Wedbush | Neutral → Outperform |
| Apr-09-26 | Upgrade | Canaccord Genuity | Hold → Buy |
| Feb-03-26 | Initiated | Wedbush | Neutral |
| Jan-16-26 | Resumed | Morgan Stanley | Underweight |
| Apr-21-25 | Initiated | Wells Fargo | Equal Weight |
| Feb-12-25 | Downgrade | BTIG Research | Buy → Neutral |
| Feb-12-25 | Downgrade | Jefferies | Buy → Hold |
| Feb-12-25 | Downgrade | Mizuho | Outperform → Neutral |
| Feb-12-25 | Downgrade | William Blair | Outperform → Mkt Perform |
| Jul-15-24 | Downgrade | Morgan Stanley | Equal-Weight → Underweight |
| Jun-11-24 | Upgrade | BTIG Research | Neutral → Buy |
| Mar-11-24 | Upgrade | Stifel | Hold → Buy |
| Dec-05-23 | Downgrade | Needham | Buy → Hold |
| Dec-04-23 | Initiated | Morgan Stanley | Equal-Weight |
| Sep-15-23 | Downgrade | The Benchmark Company | Buy → Hold |
| Aug-03-23 | Downgrade | Canaccord Genuity | Buy → Hold |
| Jun-07-23 | Downgrade | William Blair | Outperform → Mkt Perform |
| Apr-17-23 | Initiated | Piper Sandler | Neutral |
| Feb-06-23 | Downgrade | BTIG Research | Buy → Neutral |
| Dec-28-22 | Reiterated | BTIG Research | Buy |
| Dec-08-22 | Initiated | Stifel | Hold |
| Nov-07-22 | Upgrade | Sidoti | Neutral → Buy |
| Oct-14-22 | Resumed | Stephens | Overweight |
| Oct-13-22 | Initiated | Mizuho | Buy |
| Apr-08-22 | Initiated | Needham | Buy |
| Mar-28-22 | Upgrade | The Benchmark Company | Hold → Buy |
| Mar-18-22 | Upgrade | BTIG Research | Neutral → Buy |
| Jul-09-21 | Initiated | Oppenheimer | Perform |
| Jan-19-21 | Downgrade | The Benchmark Company | Buy → Hold |
| Oct-26-20 | Downgrade | Sidoti | Buy → Neutral |
| Aug-31-20 | Upgrade | Sidoti | Neutral → Buy |
| Aug-06-20 | Reiterated | The Benchmark Company | Buy |
| Jul-06-20 | Downgrade | Sidoti | Buy → Neutral |
| Jun-24-20 | Downgrade | BTIG Research | Buy → Neutral |
| Jun-15-20 | Initiated | Jefferies | Buy |
| Dec-04-19 | Initiated | BTIG Research | Buy |
| Sep-24-18 | Reiterated | The Benchmark Company | Buy |
| Aug-06-18 | Resumed | The Benchmark Company | Buy |
| Nov-20-17 | Reiterated | The Benchmark Company | Buy |
| Aug-14-17 | Reiterated | The Benchmark Company | Buy |
| Mar-03-17 | Reiterated | The Benchmark Company | Buy |
| May-18-16 | Upgrade | The Benchmark Company | Hold → Buy |
| Sep-10-13 | Resumed | The Benchmark Company | Buy |
| Feb-28-13 | Reiterated | The Benchmark Company | Buy |
| Nov-01-12 | Downgrade | Canaccord Genuity | Buy → Hold |
| Mar-02-12 | Initiated | Northland Securities | Outperform |
| Oct-25-11 | Reiterated | The Benchmark Company | Buy |
| Oct-12-10 | Initiated | Morgan Joseph | Buy |
| May-11-10 | Initiated | Benchmark | Buy |
View All
Staar Surgical Co Stock (STAA) Latest News
Midday Stock Roundup: Karman Slips - Orange County Business Journal
Has STAAR Surgical (STAA) Fallen Far Enough To Look Cheap? - Yahoo Finance
3 Reasons STAA is Risky and 1 Stock to Buy Instead - Yahoo Finance
STAAR Surgical Appoints Andrew Pilon, OD, as Vice President of Business Development - VisionMonday.com
STAAR Surgical names Andrew Pilon as VP of business development - Investing.com
A Johnson & Johnson Vision executive is joining STAAR Surgical to help build partnerships. - Stock Titan
Winners And Losers Of Q2: STAAR Surgical (NASDAQ:STAA) Vs The Rest Of The Medical Devices & SuppliesSpecialty Stocks - Yahoo Finance
STAAR Surgical Company (STAA) Stock Forecasts - Yahoo Finance
STAAR Surgical: A Recovery Story Priced As Growth - Seeking Alpha
STAAR Surgical Company (STAA) Stock Forecasts - Yahoo Finance
This Staar Surgical Analyst Turns Bullish; Here Are Top 5 Upgrades For Tuesday - webull.com
Why Staar Surgical Zoomed Almost 8% Higher on Tuesday - The Motley Fool
Why Staar Surgical Zoomed Almost 8% Higher on Tuesday - AOL.com
Why Staar Surgical Zoomed Almost 8% Higher on Tuesday - The Motley Fool
A Look at Staar Surgical Co (STAA) After 7.5% Gain -- GF Value $33.25 vs Price $22.43 - GuruFocus
STAAR Surgical Analyst Turns Bullish On Potential For ‘Meaningful’ Street Upside - Benzinga
Why is STAAR Surgical stock surging today? - Investing.com
This Staar Surgical Analyst Turns Bullish; Here Are Top 5 Upgrades For Tuesday - Benzinga
STAAR Surgical jumps on Stifel upgrade citing China growth potential - Investing.com
STAAR Surgical (STAA) Shares Skyrocket, What You Need To Know - The Chronicle-Journal
STAA Upgraded by Stifel -- Price Target Raised to $31 - GuruFocus
STAAR Surgical jumps on Stifel upgrade citing China growth potential - Yahoo Finance
Stifel upgrades STAAR Surgical stock rating on China growth outlook - Investing.com
A Look at Staar Surgical Co (STAA) After 7.5% Gain -- GF Value $33.27 vs Price $20.51 - GuruFocus
Why Staar Surgical Stock Soared Today - The Motley Fool
STAA Looks 38.4% Undervalued on GF Value™ Despite Profit Challen - GuruFocus
STAAR Surgical (STAA) Shares Skyrocket, What You Need To Know - Yahoo Finance
STAAR Surgical stock ticks higher on $50M buyback authorization - Investing.com
Why is STAAR Surgical stock climbing today? - Investing.com
STAAR Surgical authorizes $50 million share buyback program - Investing.com
STAAR Surgical Company (STAA) Stock forecasts - Yahoo Finance Singapore
STAAR Surgical stock ticks higher on $50M buyback authorization - Yahoo Finance
Is Staar Surgical Co (STAA) a Bargain After 4.1% Drop? GF Value Says Undervalued - GuruFocus
STAAR Surgical Company (STAA) Stock Forecasts - Yahoo Finance
STAAR Surgical Company (STAA) Stock Price, News, Quote & History - Yahoo! Finance Canada
STAA Rated Buy by Jefferies -- Price Target Lowered to $23 - GuruFocus
A Look at Staar Surgical Co (STAA) After 5.2% Decline -- GF Value $33.38 vs Price $21.24 - GuruFocus
STAAR Surgical (STAA) Swings To Profit On China Rebound - Yahoo Finance
STAAR Surgical (STAA) Says Implantable Lenses Are Taking Share From Laser Surgery - simplywall.st
Staar Surgical Co (STAA) Shares Fall 3.4% -- What GF Score of 81 Tells Investors - GuruFocus
STAAR Surgical hires former CEO to lead commercial team - MedTech Dive
STAAR Surgical Names David Bailey as Chief Commercial Officer with Detailed Compensation Package - Kalkine Media
STAAR Surgical Names Former CEO David Bailey as Chief Commercial Officer - Minichart
STAAR Surgical Releases Landmark Global Report Showing Structural Multi-Market Shift Toward Lens-Based Vision Correction - Finviz
U.S. laser procedures fell 52% as use of implantable lenses rose 76% - Stock Titan
STAAR Surgical Releases Landmark Global Report Showing Structural Multi-Market Shift Toward Lens-Based Vision Correction - Yahoo Finance
STAA Looks 29.6% Undervalued on GF Value™ - GuruFocus
Ex-STAAR Surgical CEO David Bailey Rejoins as Chief Commercial Officer - Medical Product Outsourcing
Former CEO returns as STAAR's vision-lens revenue grows more than tenfold - Stock Titan
Leadership watch: Samsara, Claris Bio, Staar Surgical, Wills Eye, and more - glance.eyesoneyecare.com
Staar Surgical Co Stock (STAA) Financials Data
Revenue
Net Income
Cash Flow
EPS
Staar Surgical Co Stock (STAA) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Michna Magda | Chief Development Officer |
Aug 14 '26 |
Option Exercise |
4.36 |
6,599 |
28,798 |
43,599 |
| Foust Warren | President and CEO |
Aug 14 '26 |
Option Exercise |
0.00 |
10,997 |
0 |
93,951 |
| Jiang Wei | Director |
Jun 18 '26 |
Option Exercise |
0.00 |
10,683 |
0 |
77,127 |
| Butcher Arthur C | Director |
Jun 18 '26 |
Option Exercise |
0.00 |
5,341 |
0 |
9,549 |
| SILVERMAN LOU | Director |
Jun 18 '26 |
Option Exercise |
0.00 |
10,683 |
0 |
11,158 |
| Foust Warren | Interim Co-CEO and Pres. & COO |
Mar 14 '26 |
Option Exercise |
0.00 |
29,325 |
0 |
63,588 |
| Michna Magda | Chief Development Officer |
Mar 14 '26 |
Option Exercise |
0.00 |
17,595 |
0 |
36,001 |
| BROADWOOD PARTNERS, L.P. | Director |
Mar 13 '26 |
Buy |
18.61 |
316,017 |
5,882,656 |
16,123,842 |
| BROADWOOD PARTNERS, L.P. | Director |
Mar 12 '26 |
Buy |
18.12 |
299,432 |
5,424,330 |
15,807,825 |
| Foust Warren | Interim Co-CEO and Pres. & COO |
Mar 12 '26 |
Option Exercise |
0.00 |
8,175 |
0 |
34,263 |
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):